Belkin Vision's Eagle Device for Glaucoma Receives CE Mark Under MDR

Israel-based Belkin Vision announced that it has received CE Mark for its Eagle device, making it the first automated, non-contact glaucoma laser treatment available within Europe.

Belkin Vision's Eagle Device for Glaucoma Receives CE Mark Under MDR
May 17, 2022
Ophthalmic Sciences Unveils World’s First AI Contactless Device For Measuring IOP

Israeli company Ophthalmic Sciences has unveiled the IOPerfect, which the company describes as the world's first AI-based contactless IOP measuring device.

Ophthalmic Sciences Unveils World’s First AI Contactless Device For Measuring IOP
December 03, 2021
Researchers Develop Contact Lens That Monitors Eye Pressure and Administers Glaucoma Drugs

A team of researchers working at Sun Yat-Sen University in China has developed a contact lens that can be used to monitor eye pressure changes and to administer glaucoma drugs when needed.

Researchers Develop Contact Lens That Monitors Eye Pressure and Administers Glaucoma Drugs
May 31, 2022
Nicox Receives Patent for NCX 470 in China, Extending Coverage to 2039

Nicox SA has received a formulation patent for NCX 470, its flagship pharmaceutical candidate in development for patients with open-angle glaucoma or ocular hypertension, from the Chinese National Intellectual Property Administration (CNIPA).

Nicox Receives Patent for NCX 470 in China, Extending Coverage to 2039
February 22, 2022
Researchers Use Deep Learning to Predict the Vision of Glaucoma Patients

Research from a team including the Crabb Lab at City, University of London has used 'deep learning' to predict how much their vision has been affected by the disease.

Researchers Use Deep Learning to Predict the Vision of Glaucoma Patients
June 08, 2022
Prevent Blindness to Hold 17th Annual “Eyes on Capitol Hill” Advocacy Event on March 1-2

Prevent Blindness will be holding its 17th annual Eyes on Capitol Hill advocacy day as a virtual event on March 1-2, 2022.

Prevent Blindness to Hold 17th Annual “Eyes on Capitol Hill” Advocacy Event on March 1-2
February 28, 2022
Nicox: First Patient in China Screened in Phase 3 Trial of NCX 470 for Glaucoma

Nicox SA announced that the first patient has been screened in China in the ongoing Denali phase 3 clinical trial, paving the way for new drug application (NDA) submissions in both the United States and China for NCX 470.

Nicox: First Patient in China Screened in Phase 3 Trial of NCX 470 for Glaucoma
December 20, 2021
Belkin Vision's Contactless Glaucoma Laser Receives €17.5m from European Innovation Council

Belkin Vision announced that it has received €17.5 million of blended financing in grants and equity from the European Innovation Council Accelerator (EIC).

Belkin Vision's Contactless Glaucoma Laser Receives €17.5m from European Innovation Council
December 21, 2021
Researchers Unveil New, Detailed Genetic Roadmap of Glaucoma

A new, detailed genetic roadmap of glaucoma—the world's leading cause of irreversible blindness—will help researchers develop new drugs to combat the disease, by identifying potential target areas to stall or reverse vision loss.

Researchers Unveil New, Detailed Genetic Roadmap of Glaucoma
June 13, 2022
Oculis and Accure Therapeutics Sign Licensing Agreement for Neuroprotective Drug Candidate for Glaucoma

Oculis and Accure Therapeutics have announced a licensing deal that gives Oculis the global rights to develop and commercialize ACT-01, a potentially disease-modifying medication that protects and prevents optic nerve and retina damage.

Oculis and Accure Therapeutics Sign Licensing Agreement for Neuroprotective Drug Candidate for Glaucoma
March 09, 2022
Daha fazla